Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.

Leukemia - 1 Aug 2024

Pozzo Federico, Forestieri Gabriela, Vit Filippo, Ianna Giulia, Tissino Erika, Bittolo Tamara, Papotti Robel, Gaglio Annalisa, Terzi di Bergamo Lodovico, Steffan Agostino, Polesel Jerry, Bulian Pietro, Laureana Roberta, Tafuri Agostino, Chiarenza Annalisa, Di Raimondo Francesco, Olivieri Jacopo, Zaja Francesco, Laurenti Luca, Del Principe Maria Ilaria, Postorino Massimiliano, Del Poeta Giovanni, Bomben Riccardo, Zucchetto Antonella, Rossi Davide, Gattei Valter

Abstract excerpt

The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib represents an effective strategy for treatment of chronic lymphocytic leukemia (CLL), nevertheless about 30% of patients eventually undergo disease progression. Here we investigated by flow cytometry the long-term modulation of the CLL CXCR4dim/CD5bright proliferative fraction (PF), its correlation with therapeutic outcome and emergence of ibrutinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Agammaglobulinaemia Tyrosine Kinase

Share to CD5 Antigens

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Phospholipase C gamma

Share to Piperidines

Share to Pyrazoles

Share to Receptors, CXCR4

Source

Open in PubMed Open full text

Identifiers

PMID: 38914716
DOI: 10.1038/s41375-024-02301-y
PMCID: PMC11286529

Genes

BTK
PLCG2
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.PMID 38914716Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinibSemantic proximity Read ↗

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSemantic proximity Read ↗

The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Semantic proximity Read ↗

Therapy-driven clonal dynamics in chronic lymphocytic leukemia.Semantic proximity Read ↗

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.Semantic proximity Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

Epigenomic evolution in chronic lymphocytic leukaemia cells from patients treated with ibrutinib and showing disease progressionSemantic proximity Read ↗

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy.Semantic proximity Read ↗

Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLLSemantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.